Acalabrutinib for mantle cell lymphoma

Thomas E. Witzig; David Inwards

doi:10.1182/blood.2019852368

Acalabrutinib for mantle cell lymphoma

Thomas E. Witzig, David Inwards

Hematology

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Mantle cell lymphoma (MCL) is a unique type of non-Hodgkin lymphoma characterized by the overexpression of cyclin D1. MCL patients typically live for years but experience multiple relapses. Acalabrutinib is a novel second-generation oral Bruton tyrosine kinase inhibitor approved by the US Food and Drug Administration for relapsed MCL based on a clinical trial demonstrating an overall response rate of 81%. It provides a valuable new treatment option for MCL patients and is now being tested upfront.

Original language	English (US)
Pages (from-to)	2570-2574
Number of pages	5
Journal	Blood
Volume	133
Issue number	24
DOIs	https://doi.org/10.1182/blood.2019852368
State	Published - 2019

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood.2019852368

Cite this

@article{b37e2f0411864eb7a6d5e00498208475,

title = "Acalabrutinib for mantle cell lymphoma",

abstract = "Mantle cell lymphoma (MCL) is a unique type of non-Hodgkin lymphoma characterized by the overexpression of cyclin D1. MCL patients typically live for years but experience multiple relapses. Acalabrutinib is a novel second-generation oral Bruton tyrosine kinase inhibitor approved by the US Food and Drug Administration for relapsed MCL based on a clinical trial demonstrating an overall response rate of 81%. It provides a valuable new treatment option for MCL patients and is now being tested upfront.",

author = "Witzig, {Thomas E.} and David Inwards",

note = "Funding Information: The Mayo Clinic received research funding from Acerta Pharmaceuticals to conduct the trials. No direct remuneration was provided to the authors. Publisher Copyright: {\textcopyright} 2019 by The American Society of Hematology.",

year = "2019",

doi = "10.1182/blood.2019852368",

language = "English (US)",

volume = "133",

pages = "2570--2574",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "24",

}

TY - JOUR

T1 - Acalabrutinib for mantle cell lymphoma

AU - Witzig, Thomas E.

AU - Inwards, David

N1 - Funding Information: The Mayo Clinic received research funding from Acerta Pharmaceuticals to conduct the trials. No direct remuneration was provided to the authors. Publisher Copyright: © 2019 by The American Society of Hematology.

PY - 2019

Y1 - 2019

N2 - Mantle cell lymphoma (MCL) is a unique type of non-Hodgkin lymphoma characterized by the overexpression of cyclin D1. MCL patients typically live for years but experience multiple relapses. Acalabrutinib is a novel second-generation oral Bruton tyrosine kinase inhibitor approved by the US Food and Drug Administration for relapsed MCL based on a clinical trial demonstrating an overall response rate of 81%. It provides a valuable new treatment option for MCL patients and is now being tested upfront.

AB - Mantle cell lymphoma (MCL) is a unique type of non-Hodgkin lymphoma characterized by the overexpression of cyclin D1. MCL patients typically live for years but experience multiple relapses. Acalabrutinib is a novel second-generation oral Bruton tyrosine kinase inhibitor approved by the US Food and Drug Administration for relapsed MCL based on a clinical trial demonstrating an overall response rate of 81%. It provides a valuable new treatment option for MCL patients and is now being tested upfront.

UR - http://www.scopus.com/inward/record.url?scp=85068040922&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068040922&partnerID=8YFLogxK

U2 - 10.1182/blood.2019852368

DO - 10.1182/blood.2019852368

M3 - Article

C2 - 30967367

AN - SCOPUS:85068040922

SN - 0006-4971

VL - 133

SP - 2570

EP - 2574

JO - Blood

JF - Blood

IS - 24

ER -

Acalabrutinib for mantle cell lymphoma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this